Alstom SA (AOMD)
XETRA Stock Exchange · Germany · prices in EUR · close of 19 Oct 2026
Key indicators
| Last close | EUR 15.97 |
|---|---|
| 52-week range | 14.49 – 30.09 |
| Return, 1 month / 3 months | +3.8% / −0.7% |
| Return, 1 year / 3 years | −26.6% / +37.3% |
| Trend | Below its 200-day average |
| RSI (14) | 54 |
| Volatility (1 year) | 45.0% |
| Worst drawdown (1 year) | -51.4% |
| Average daily value traded | 0.12M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Alstom is a rail transport company based in France that designs and builds trains, including high-speed, regional and metro rolling stock, along with trams and locomotives. It also supplies signalling and control systems, and provides maintenance and modernisation services for rail networks. Its customers are passenger and freight rail operators, transit authorities and infrastructure owners in many countries, who rely on the company for equipment and long-term service support across their fleets and lines.
On this site Alstom SA appears as a stock on the XETRA Stock Exchange (Germany), code AOMD, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 3 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Alstom SA (AOMD) trades on the XETRA Stock Exchange in Germany. It last closed at EUR 15.97 on 19 October 2026.
Its price-based Market X-Ray is 29 out of 100 (a weak price profile), ranking 579 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 26.6% and over the last three months it fell 0.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on XETRA Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 14 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -18.4% | ||
| From 52-week high | -46.5% | ||
| Momentum | 38 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -0.7% | ||
| 6-month return | -6.4% | ||
| 12-month return, skipping the last month | -29.3% | ||
| Risk (lower is better) | 24 · Weak | Volatile, with deep drawdowns. | |
| Volatility (1 year) | 45.0% | ||
| Worst drawdown (1 year) | -51.4% | ||
| Liquidity | 46 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.12M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 2 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Risk (lower is better): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +0.0% |
|---|---|
| 1 month | +3.8% |
| 3 months | −0.7% |
| 6 months | −6.4% |
| 1 year | −26.6% |
| 3 years | +37.3% |
| 5 years | – |
Signals
| 50-day / 200-day average | 15.79 / 19.58 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.41 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 17 Jul 2023 | EUR 0.2359 |
| 20 Jul 2022 | EUR 0.2359 |
| 2 Aug 2021 | EUR 0.2359 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on XETRA Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.